SCHEMBL22441586

SCHEMBL22441586

COc1ccc2c(N3CCC(C(C)CN)CC3)ccnc2c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
NCF1 P14598 2/20 0.48
FERMT2 Q96AC1 1/20 0.44
NPC1 O15118 1/20 0.43
HTR1A P08908 2/20 0.42
ADRA1D P25100 2/20 0.42
ADRA1A P35348 2/20 0.42
ADRA1B P35368 2/20 0.42
CYP8B1 Q9UNU6 1/20 0.41
ALDH1A1 P00352 2/20 0.41
IDE P14735 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
CASP1 P29466 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CHKA P35790 1/20 0.39
CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22445498 1.00 GAA (0.50) GAANCF1FERMT2NPC1HTR1A
SCHEMBL29354630 1.00 GAA (0.50) GAANCF1FERMT2NPC1HTR1A
SCHEMBL22445512 0.91 NCF1 (0.60) GAANCF1HTR1AADRA1DADRA1A
SCHEMBL22441530 0.91 NCF1 (0.60) GAANCF1HTR1AADRA1DADRA1A
SCHEMBL22445574 0.88 GAA (0.55) GAANCF1NPC1HTR1AADRA1D
SCHEMBL22441558 0.86 NCF1 (0.59) NCF1NPC1HTR1A
SCHEMBL22445487 0.86 NCF1 (0.59) NCF1NPC1HTR1A
SCHEMBL22441609 0.84 ENPP1 (0.48) GAANCF1FERMT2NPC1HTR1A
SCHEMBL31457626 0.84 ENPP1 (0.48) GAANCF1FERMT2NPC1HTR1A
SCHEMBL28684968 0.84 GAA (0.45) GAANCF1FERMT2NPC1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3941459-B1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2026-05-06 EP disclosed
US-11407729-B2 Quinoline and quinazoline compounds and methods of use thereof Stingray Therapeutics, Inc. (US) 2022-08-09 US disclosed
US-11407729-B2 Quinoline and quinazoline compounds and methods of use thereof Stingray Therapeutics, Inc. (US) 2022-08-09 US disclosed
CN-113924092-A Quinoline and quinazoline compounds and methods of use thereof 斯汀格瑞治疗股份有限公司 2022-01-11 CN disclosed
US-20200299258-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2020-09-24 US disclosed
US-20200299258-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2020-09-24 US disclosed
WO-2020190912-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF Stingray Therapeutics, Inc. (US) 2020-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299258-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ENPP1, ENPP3, PDE7A GAA 267/4885NCF1 283/4885FERMT2 3980/4885
US-11407729-B2 Quinoline and quinazoline compounds and methods of use thereof ENPP1, ENPP3, PDE7A GAA 267/4885NCF1 283/4885FERMT2 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.